BAY 443428

Drug Profile

BAY 443428

Latest Information Update: 25 May 2000

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Celera Genomics Group
  • Developer Bayer; Celera Genomics Group
  • Class Antiasthmatics
  • Mechanism of Action Tryptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 25 May 2000 Discontinued-Preclinical for Asthma in USA (PO)
  • 05 Mar 1999 BAY 443428 selected as the lead compound of the oral tryptase inhibitor programme
  • 15 Oct 1998 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top